Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

Wave Life Sciences (WVE) Shares Issued (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Shares Issued for 12 consecutive years, with $1.9 million as the latest value for Q1 2026.

For Q1 2026, Shares Issued rose 337.56% year-over-year to $1.9 million; the TTM value through Mar 2026 reached $16.4 million, up 226.46%, while the annual FY2025 figure was $14.9 million, 2156.15% up from the prior year.
Shares Issued hit $1.9 million in Q1 2026 for Wave Life Sciences, down from $14.0 million in the prior quarter.
Across five years, Shares Issued topped out at $51.2 million in Q3 2022 and bottomed at -$50.9 million in Q4 2022.
Average Shares Issued over 5 years is $1.4 million, with a median of $439000.0 recorded in 2025.
On a YoY basis, Shares Issued climbed as much as 59632.56% in 2022 and fell as far as 14307.54% in 2022.
Wave Life Sciences' Shares Issued stood at -$50.9 million in 2022, then soared by 101.23% to $627000.0 in 2023, then tumbled by 50.56% to $310000.0 in 2024, then soared by 4411.94% to $14.0 million in 2025, then crashed by 86.17% to $1.9 million in 2026.
According to Business Quant data, Shares Issued over the past three periods came in at $1.9 million, $14.0 million, and $439000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.